SynerFuse announces presentation of IDE proof-of-concept study data
SynerFuse has announced that Michael Park (University of Minnesota, Minneapolis, USA)—principal investigator for the company’s investigational device exemption (IDE) proof-of-concept study—presented data from the study’s...
Biotronik announces US FDA approval of Prospera spinal cord stimulation system
Biotronik has announced US Food and Drug Administration (FDA) approval for Prospera—a new spinal cord stimulation (SCS) system. The system features RESONANCE, which the...
Review concludes SCS benefits do not outweigh associated risks and costs in low back...
A recently published Cochrane review has concluded that the clinical benefits of spinal cord stimulation (SCS) do not outweigh the risks and costs associated...
Synaptive announces US and Canadian availability of Modus X
Synaptive Medical has announced US Food and Drug Administration (FDA) registration of its next-generation robotic exoscope, Modus X.
Modus X, which is the fourth generation...
